Shock - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 41

Shock - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Shock - Pipeline Review, Q2 2011', provides an overview of the Shock therapeutic pipeline. This report provides information on the therapeutic development for Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shock. 'Shock - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Shock.
- A review of the Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Shock pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Shock pipeline depth and focus of Shock therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Shock Overview
Therapeutics Development
An Overview of Pipeline Products for Shock
Shock Therapeutics under Development by Companies
Shock Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Shock Therapeutics - Products under Development by Companies
Shock Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Shock Therapeutics Development
Athersys, Inc.
Curacyte AG
Ikaria Inc.
Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MultiStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemoximer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemoximer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IK-6001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pyruvate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Shock Therapeutics – Drug Profile Updates
Shock - Featured News
Mar 28, 2011: Curacyte Reports PHOENIX Phase III Trial Of PHP For Distributive Shock To Continue After Positive Midpoint Recommendation From DMB
Jun 05, 2009: Curacyte Reports Enrollement Of First Patient In The PHOENIX Trial For The Drug Hemoximer
Jan 10, 2008: Curacyte Receives US Orphan Drug Designation for Cardiogenic Shock Drug, Hemoximer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Shock, Q2 2011
Products under Development for Shock – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Athersys, Inc., 2011
Curacyte AG, 2011
Ikaria Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Shock Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Shock, Q2 2011
Products under Development for Shock – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Shock - Pipeline Review, H2 2012
• Cardiogenic Shock - Pipeline Review, H2 2011
• Cardiogenic Shock - Pipeline Review, H1 2012
• Shock - Pipeline Review, H2 2011
• Septic Shock - Pipeline Review, H1 2013
• Hemorrhagic Shock - Pipeline Review, H2 2012
• Shock - Pipeline Review, H1 2012
• Septic Shock - Pipeline Review, H2 2012
• Shock Global Clinical Trials Review, H2, 2012
• Septic Shock Global Clinical Trials Review, H2, 2012